Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan and dapagliflozin dose-ranging study in chronic kidney disease
NL-OMON52170Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zibotentan and dapagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in log-transformed UACR from baseline to Week 12. Started Feb 2021; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON52170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52170.